

Ir-Renju Unit-Runcorn: Prodotti farmaċewtiċi

OJ S 194/2020 06/10/2020

Avviż dwar kuntratt

Fornituri

Il-bażi ġuridika:

Direttiva 2014/24/UE

Taqsim I: Awtorità kontraenti

I.1. Isem u indirizzi

Isem uffiċjali: The NHS Commissioning Board (operating under the name of NHS England)

Indirizz postali: 2nd Floor, Rutland House

Belt: Runcorn

Kodiċi NUTS: UK United Kingdom

Kodiċi postali: WA7 2ES

Pajjiż: Ir-Renju Unit

Persuna ta' kuntatt: Katie Noonan

Posta elettronika: katie.noonan@nhs.net**Indirizz(i) tal-Internet:**Indirizz ewlieni: <https://www.england.nhs.uk/>Indirizz tal-profil tax-xerrej: <https://www.england.nhs.uk/>**I.2. Tagħrif dwar ksib kongunt**

Il-kuntratt qed jingħata minn korp ċentrali għall-akkwisti

I.3. KomunikazzjoniId-dokumenti tal-akkwist huma disponibbli għal aċċess mingħajr restrizzjoni u dirett sħiħ, mingħajr ħlas, fuq: <http://health.atamis.co.uk>

Aktar informazzjoni tista' tinkiseb minn l-indirizz imsemmi hawn fuq

Offerti jew talbiet għall-partecipazzjoni għandhom jintbagħtu b'mod elettroniku permezz ta': <http://health.atamis.co.uk>

Offerti jew talbiet għall-partecipazzjoni għandhom jintbagħtu l-indirizz imsemmi hawn fuq

Il-komunikazzjoni elettronika teħtieġ l-użu ta' għodod u strumenti li mhux soltu ssibhom.

Aċċess mingħajr restrizzjoni u dirett sħiħ għal dawn l-għodod u strumenti huwa possibbli, mingħajr ħlas, fuq: <http://health.atamis.co.uk>**I.4. Tip ta' awtorità kontraenti**

Ministeru jew kull awtorità nazzjonali jew federali oħra, inklużi s-sottodivizionijiet reġjonali jew lokali tagħhom

I.5. Attività ewlenija

Saħħa

Taqsim II: L-għan

II.1. L-għan tal-ksib**II.1.1. Titlu**

NHS Framework for the Midlands and East, Branded Medicines — Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.

Numru ta' referenza: CM/PHR/20/5591

II.1.2. Kodiċi ewlieni CPV

33600000 Prodotti farmaċewtiċi

II.1.3. It-tip ta' kuntratt

Provvisti

II.1.4. Deskrizzjoni qasira

CM/PHR/20/5591/01 — Midlands and East, Branded Medicines — Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

CM/PHR/20/5591/02 — Midlands and East Branded Medicines — Annual Tranche, cytokine modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for migraine and asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

CM/PHR/20/5591/03 — Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021.

CM/PHR/20/5591/04 — Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021.

II.1.5. Stima tal-valur totali

Valur mingħajr VAT: 754 830 788,00 GBP

II.1.6. Informazzjoni dwar il-lottijiet

Dan il-kuntratt huwa maqsum f'lottijiet: iva

L-offerti jistgħu jintbagħtu għal il-lottijiet kollha

II.2. Deskrizzjoni

II.2.1. Titlu

Lot 4: (SOFE) — Interleukin Inhibitors, JAK Inhibitors, Migraine and Asthma

Nru tal-lott: 4

II.2.2. Kodiċi(jiet) addizzjonali tal-VKK

33600000 Prodotti farmaċewtiċi

II.2.3. Il-post tat-twettiq

Kodiċi NUTS: UK United Kingdom

Is-sit jew post ewlieni tal-eżekuzzjoni: Please refer to document No 10 for a full list of participating authorities.

II.2.4. Deskrizzjoni tal-akkwist

CM/PHR/20/5591/04 — NHS Framework agreement for the supply of interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021.

II.2.5. Kriterji tal-għoti

Il-prezz mhuwiex il-kriterju waħdani għall-għoti u l-kriterji kollha huma msemmija biss fid-dokumenti tal-ksib

II.2.6. Stima tal-valur

II.2.7. Tul tal-kuntratt, qafas ta' ftehim jew sistema dinamika ta' xiri

Bidu: 01/03/2021 Tmiem: 31/08/2021

Dan il-kuntratt huwa soġġett għal tiġdid: le

II.2.10. Informazzjoni dwar il-varjanti

Il-varjanti se jiġu aċċettati: iva

II.2.11. Informazzjoni dwar l-għażliet

Għażliet: le

II.2.13. Informazzjoni dwar Fondi tal-Unjoni Ewropea

L-akkwist huwa marbut ma' proġett u/jew programm iffinanzjat mill-fondi tal-Unjoni Ewropea: le

II.2.14. Informazzjoni addizzjonali

II.2. Deskrizzjoni

II.2.1. Titlu

Lot 3: (LNW) — Interleukin Inhibitors, JAK Inhibitors, Migraine and Asthma

Nru tal-lott: 3

II.2.2. Kodiċi(jiet) addizzjonali tal-VKK

33600000 Prodotti farmaċewtiċi

II.2.3. Il-post tat-twettiq

Kodiċi NUTS: UK United Kingdom

Is-sit jew post ewlieni tal-eżekuzzjoni: Please refer to document No 10 for a full list of participating authorities.

II.2.4. Deskrizzjoni tal-akkwist

CM/PHR/20/5591/03 — NHS Framework agreement for the supply of interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021.

II.2.5. Kriterji tal-għoti

Il-prezz mhuwiex il-kriterju waħdani għall-għoti u l-kriterji kollha huma msemmija biss fid-dokumenti tal-ksib

II.2.6. Stima tal-valur

II.2.7. Tul tal-kuntratt, qafas ta' ftehim jew sistema dinamika ta' xiri

Bidu: 01/03/2021 Tmiem: 31/08/2021

Dan il-kuntratt huwa soġġett għal tiġdid: le

II.2.10. Informazzjoni dwar il-varjanti

Il-varjanti se jiġu aċċettati: iva

II.2.11. Informazzjoni dwar l-għażliet

Għażliet: le

II.2.13. Informazzjoni dwar Fondi tal-Unjoni Ewropea

L-akkwist huwa marbut ma' proġett u/jew programm iffinanzjat mill-fondi tal-Unjoni Ewropea: le

II.2.14. Informazzjoni addizzjonali

II.2. Deskrizzjoni

II.2.1. Titlu

Lot 2: Midlands and East Cytokine Modulators and Other Monoclonal Antibodies
Nru tal-lott: 2

II.2.2. Kodiċi(jiet) addizzjonali tal-VKK

33600000 Prodotti farmaċewtiċi

II.2.3. Il-post tat-twettiq

Kodiċi NUTS: UK United Kingdom

Is-sit jew post ewlieni tal-eżekuzzjoni: Please refer to document No 10 for a full list of participating authorities.

II.2.4. Deskrizzjoni tal-akkwist

CM/PHR/20/5591/02 — NHS Framework for the Midlands and East Branded Medicines — annual tranche, cytokine modulators, other monoclonal antibodies interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

II.2.5. Kriterji tal-għoti

Il-prezz mhuwiex il-kriterju waħdani għall-għoti u l-kriterji kollha huma msemmija biss fid-dokumenti tal-ksib

II.2.6. Stima tal-valur

II.2.7. Tul tal-kuntratt, qafas ta' ftehim jew sistema dinamika ta' xiri

Bidu: 01/03/2021 Tmiem: 28/02/2022

Dan il-kuntratt huwa soġġett għal tiġdid: le

II.2.10. Informazzjoni dwar il-varjanti

Il-varjanti se jiġu aċċettati: iva

II.2.11. Informazzjoni dwar l-għażliet

Għażliet: iva

Deskrizzjoni ta' għażliet:

There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

II.2.13. Informazzjoni dwar Fondi tal-Unjoni Ewropea

L-akkwist huwa marbut ma' proġett u/jew programm iffinanzjat mill-fondi tal-Unjoni Ewropea: le

II.2.14. Informazzjoni addizzjonali

II.2. Deskrizzjoni

II.2.1. Titlu

Lot 1: Midlands and East (MAE) Tranche B
Nru tal-lott: 1

II.2.2. Kodiċi(jiet) addizzjonali tal-VKK

33600000 Prodotti farmaċewtiċi

II.2.3. Il-post tat-twettiq

Kodiċi NUTS: UK United Kingdom

Is-sit jew post ewlieni tal-eżekuzzjoni: Please refer to document No 10 for a full list of participating authorities.

II.2.4. Deskrizzjoni tal-akkwist

CM/PHR/20/5591/01 — NHS Framework for the Midlands and East, Branded Medicines — Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

II.2.5. Kriterji tal-għoti

Il-prezz mhuwiex il-kriterju waħdani għall-għoti u l-kriterji kollha huma msemmija biss fid-dokumenti tal-ksib

II.2.6. Stima tal-valur

II.2.7. Tul tal-kuntratt, qafas ta' ftehim jew sistema dinamika ta' xiri

Bidu: 01/03/2021 Tmiem: 28/02/2022

Dan il-kuntratt huwa soġġett għal tiġdid: Ie

II.2.10. Informazzjoni dwar il-varjanti

Il-varjanti se jiġu aċċettati: iva

II.2.11. Informazzjoni dwar l-għażliet

Għażliet: iva

Deskrizzjoni ta' għażliet:

There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

II.2.13. Informazzjoni dwar Fondi tal-Unjoni Ewropea

L-akkwist huwa marbut ma' proġett u/jew programm iffinanzjat mill-fondi tal-Unjoni Ewropea: Ie

II.2.14. Informazzjoni addizzjonali

Taqsimha III: Informazzjoni legali, ekonomika, finanzjarja u teknika

III.1. Kondizzjonijiet għall-partecipazzjoni

III.1.2. Qagħda ekonomika u finanzjarja

Kriterji tal-għażla kif jidhru fid-dokumenti tal-akkwist

Taqsimha IV: Proċedura

IV.1. Deskrizzjoni

IV.1.1. Tip ta' proċedura

Proċedura miftuħa

IV.1.3. Informazzjoni dwar ftehim qafas jew sistema dinamika ta' xiri

Il-ksib jinvolvi t-twaqqif ta' qafas ta' ftehim

Ftehim qafas b'diversi operaturi

IV.1.8. Informazzjoni dwar il-Ftehim dwar l-Akkwisti Pubbliċi (GPA)

L-akkwist huwa kopert mill-GPA: iva

IV.2. Informazzjoni amministrattiva

IV.2.2. Limitu ta' żmien għall-wasla tal-offerti jew it-talbiet għall-partecipazzjoni

Data: 05/11/2020 Ħin lokali: 13:00

IV.2.3. Id-data maħsuba għad-dispaċċ tal-istediniet għall-offerti jew għas-sehem lil kandidati magħżula

IV.2.4. Lingwi li bihom jistgħu jkunu sottomessi l-offerti jew it-talbiet għall-partecipazzjoni Ingliz

IV.2.6. Perjodu ta' żmien minimu li matulu l-offerent għandu jzomm l-offerta

Is-sejha għall-offerti trid tibqa' valida sa: 03/02/2021

IV.2.7. Kundizzjonijiet għall-ftuħ tal-offerti

Data: 05/11/2020 Ħin lokali: 13:00

Post:

Runcorn.

Informazzjoni dwar persuni awtorizzati u l-proċedura tal-ftuħ: Commercial Medicines Unit employee.

Taqsim VI: Informazzjoni kumplimentari

VI.1. Informazzjoni dwar rikorrenza

Dan huwa akkwist rikorrenti: le

VI.2. Informazzjoni dwar flussi ta' xogħol elettronici

Se jintużaw ordnijiet elettronici

Se jkun aċċettat il-ħruġ ta' fatturi elettronici

Se jintużaw pagamenti elettronici

VI.3. Informazzjoni addizzjonali

Responding to this notice

Any supplier may be disqualified who does not respond to the following in the requisite manner.

1) Submission of expression of interest and procurement specific information

This procurement exercise will be conducted on the eTendering portal at <https://health-family.force.com/s/Welcome> Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:

1.1) if not already registered, candidates should register on the eTendering portal at

<https://health-family.force.com/s/Welcome> and click the link to register:

— agree to the user agreement,

— populate company details;

1.2) once registered, candidates must register interest as follows:

— log to the portal,

— select 'Find Opportunities' from the supplier home screen, use the 'Sort by': facility to find this opportunity and select the bold blue title to select,

— review opportunity details and click 'Register Interest',

— as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity);

1.3) there is a supplier user guide on using the system and candidates can contact the Atamis helpdesk at support-health@atamis.co.uk or by calling 08009956035 for technical assistance when completing responses.

2) General supplier information.

To manage and assess supplier information the contracting authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows.

2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page <https://supplierregistration.cabinetoffice.gov.uk> and select 'Register' at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.

2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B.

2.3) For further help or information concerning this telephone +44(0) 1614137982 or via the message function on the website.

Other contracting authorities

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

VI.4. Proċeduri ta' analiżi mill-ġdid

VI.4.1. Korp responsabbli għall-proċeduri ta' analiżi mill-ġdid

Isem uffiċjali: The High Court

Indirizz postali: Strand

Belt: London

Kodiċi postali: WC2A 2LL

Pajjiż: Ir-Renju Unit

Indirizz tal-Internet: <https://www.gov.uk/courts-tribunals>

VI.5. Data ta' meta ntbagħat dan l-avviż

01/10/2020